Gov. Andrew Cuomo is asking state lawmakers to revive a tax on the sale of opioids in New York in an effort to curb drug overdoses after a similar law was struck down by a federal judge as unconstitutional late last year.
But unlike the now-defunct Opioid Stewardship Act, the cost of that tax on opioid companies would be allowed to be passed on to consumers who are prescribed those drugs, according to the legislation, which has the potential to raise prices.
The first attempt at imposing an opioid tax by state law was struck down largely over a provision that barred companies from passing the cost of the surcharge onto their customers. U.S. District Judge Katherine Polk Failla of the Southern District of New York wrote in a decision in December that the so-called pass-through provision of the law violated the dormant commerce clause of the U.S. Constitution.
“New York’s position is seriously, if not mortally, wounded by the fact that the text of the OSA places no such limitation on the pass-through prohibition,” Failla wrote. “If OSA’s provisions are given their clearest meaning, the dormant commerce clause violation is clear.”
The law may have forced companies to, instead, impose the cost of New York’s opioid tax on consumers in other states, Failla wrote. The new proposal would avoid that conflict by allowing the expense to be passed on to consumers regardless of their location.
“The economic incidence of the tax imposed by this article may be passed to a purchaser,” the legislation reads.
The new proposal would also change how and when the tax is collected, two provisions that were challenged in the lawsuit last year. The litigation was brought by the Healthcare Distribution Alliance, an organization representing pharmaceutical distributors.
A spokesman for the organization said they were reviewing the new proposal and declined to initially comment on it.
They took issue with how the state planned to collect the surcharge in the previous law. The state had planned to require opioid manufacturers and distributors to collectively pay $100 million to the state over six years. The amount each company was expected to pay would have been determined based on the share of business they report in New York.
Opioid companies challenged that part of the law because they said it took the amount they would pay out of their hands, and put it at risk of another company’s choices.
The state is still expected to generate $100 million from the tax, but it would be collected differently. It would be set like a sales tax paid quarterly by opioid companies rather than a surcharge paid annually as it was in the previous law.
If the manufacturer’s list price to wholesalers or direct purchasers for an opioid unit is less than 50 cents, they would pay a quarter of a cent per morphine milligram equivalent, or the strength of the drug compared to morphine as determined by the state Department of Health. If the list price is more than 50 cents, that company would pay 1.5 cents per morphine milligram equivalent.
The first round of taxes paid by each company would be based on the amount they sell between when the legislation is signed and Jan. 20, 2020. After that, the tax would be paid by companies each quarter based on reports filed with the state.
That method is also different from the previous version, which would have had companies make their initial payment to the state based on sales from before the law was passed. HDA had argued against that provision of the statute in their lawsuit, saying it was unlawful for the state to impose such a charge on retroactive sales.
The reports sent to the state on those sales would not be made public, according to the legislation. If a state employee makes them public or divulges any information from them without a court order, the legislation would allow them to be fired.
Cuomo included the new proposal in his 30-day budget amendments, which are released a month after the governor presents his executive budget proposal to the Legislature each year. Lawmakers were supportive of the proposal last year.
The state budget is due by the end of March.